LOC100289473: A Drug Target / Disease Biomarker (G100289473)
LOC100289473: A Drug Target / Disease Biomarker
LOC100289473 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of G-coupled proteins, which are a type of transmembrane protein that consists of a cytoplasmic domain and a transmembrane region.
The protein encoded by LOC100289473 is approximately 180 amino acids long and has a calculated pI of 9.95. It is expressed in a variety of tissues and is involved in several cellular processes, including cell signaling, cell adhesion, and neurotransmitter signaling.
One of the most promising aspects of LOC100289473 is its potential as a drug target. LOC100289473 has been shown to interact with several protein molecules, including the neurotransmitter GABA and the transcription factor NF-kappa-B. This suggests that LOC100289473 may play a role in the regulation of neurotransmitter signaling and may be a useful target for drugs that target these processes.
In addition to its potential as a drug target, LOC100289473 has also been shown to be involved in several other cellular processes. For example, LOC100289473 has been shown to be involved in the regulation of cell adhesion, as well as in the development and maintenance of neural stem cells.
Overall, LOC100289473 is a protein that has the potential to be a drug target for a variety of psychiatric and neurological disorders. Further research is needed to fully understand its role in these processes and to develop effective treatments.
Protein Name: Cytoskeleton Associated Protein 2-like Pseudogene
The "LOC100289473 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100289473 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC100289495 | LOC100289511 | LOC100289561 | LOC100289580 | LOC100289656 | LOC100293211 | LOC100294145 | LOC100335030 | LOC100419773 | LOC100420587 | LOC100421561 | LOC100505498 | LOC100505502 | LOC100505585 | LOC100505664 | LOC100505715 | LOC100505716 | LOC100505841 | LOC100505912 | LOC100505915 | LOC100505978 | LOC100506023 | LOC100506071 | LOC100506076 | LOC100506124 | LOC100506207 | LOC100506236 | LOC100506274 | LOC100506281 | LOC100506379 | LOC100506403 | LOC100506422 | LOC100506444 | LOC100506446 | LOC100506472 | LOC100506474 | LOC100506499 | LOC100506514 | LOC100506532 | LOC100506606 | LOC100506634 | LOC100506639 | LOC100506667 | LOC100506730 | LOC100506974 | LOC100507002 | LOC100507006 | LOC100507053 | LOC100507054 | LOC100507156 | LOC100507165 | LOC100507221 | LOC100507250 | LOC100507336 | LOC100507346 | LOC100507351 | LOC100507389 | LOC100507412 | LOC100507424 | LOC100507443 | LOC100507513 | LOC100507520 | LOC100507547 | LOC100507577 | LOC100507656 | LOC100509646 | LOC100533709 | LOC100630923 | LOC100652743 | LOC100652768 | LOC100652833 | LOC100652999 | LOC100653061 | LOC100996385 | LOC100996412 | LOC100996583 | LOC100996637 | LOC100996643 | LOC100996664 | LOC100996770 | LOC101060017 | LOC101060106 | LOC101060179 | LOC101060400 | LOC101060445 | LOC101060524 | LOC101060632 | LOC101448202 | LOC101593348 | LOC101926887 | LOC101926948 | LOC101926953 | LOC101926959 | LOC101926969 | LOC101927002 | LOC101927020 | LOC101927025 | LOC101927026 | LOC101927040 | LOC101927053
